CoChat

Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

In colorectal cancer (CRC), attempts to identify cancer cell-specific markers to guide antibody-mediated therapeutics have failed to uncover markers that are both exclusive to cancer tissues and abundant across CRCs. Alternatively, cancer-associated fibroblasts (CAFs), which are abundant in the tumor microenvironment and upregulate unique surface markers, are not found in healthy tissues. Here, we evaluated the expression patterns of CAF-associated proteins α-smooth muscle actin (αSMA), fibroblast activation protein (FAP), podoplanin (PDPN), matrix metalloproteinase-2 (MMP2), transgelin (TAGLN), and THY1. While αSMA and THY1 were abundant in cancer tissues, high abundance in normal tissues limited their targeting potential. FAP was present in 94.5% of primary and metastatic CRC tissues and absent in 93.7% of adjacent normal colon and liver tissues assessed. These results indicate that FAP is a promising target for antibody conjugates with potential for broad application in CRC. Co-expression analyses showed that CRCs simultaneously expressing high levels of PDPN, MMP2, and THY1 were enriched for immune-related signatures, indicating potential for antibody-mediated immune engagers. Overall, this work highlights the potential of CAF proteins to act as therapeutic targets for novel anticancer agents and become important therapeutic biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers16183158

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CAF marker expression in CRC patient tissues. Tissue microarrays with patient CRC tissues were stained with CAF markers and scored 0–3+. (A) Representative staining and scoring for αSMA, FAP, and THY1 in CRC tissues across tissue microarrays. Scale bar = 50 µm. (B) Frequency of marker-absent (score 0), marker-low (score 1), and marker-high (score 2–3) CRC tissue samples for each CAF marker (αSMA, collagen, FAP, MMP2, PDPN, TAGLN, and THY1) (C) Correlations between marker expression scores across all CRC tissues were evaluated by Pearson’s Correlation tests performed on all pairs of CAF markers. Strength of correlation was binned by correlation coefficient, where a correlation coefficient (r) ≥ 0.6 indicated a strong positive correlation, 0.3 ≤ r < 0.6 indicated a weak positive correlation, −0.3 ≤ r < 0.3 indicated no correlation, −0.6 ≤ r < −0.3 indicated a weak negative (inverse) correlation, and r < −0.6 indicated a strong negative (inverse) correlation. Asterisks denote statistical significance (p < 0.05).
Figure 1 CAF marker expression in CRC patient tissues. Tissue microarrays with patient CRC tissues were stained with CAF markers and scored 0–3+. (A) Representative staining and scoring for αSMA, FAP, and THY1 in CRC tissues across tissue microarrays. Scale bar = 50 µm. (B) Frequency of marker-absent (score 0), marker-low (score 1), and marker-high (score 2–3) CRC tissue samples for each CAF marker (αSMA, collagen, FAP, MMP2, PDPN, TAGLN, and THY1) (C) Correlations between marker expression scores across all CRC tissues were evaluated by Pearson’s Correlation tests performed on all pairs of CAF markers. Strength of correlation was binned by correlation coefficient, where a correlation coefficient (r) ≥ 0.6 indicated a strong positive correlation, 0.3 ≤ r < 0.6 indicated a weak positive correlation, −0.3 ≤ r < 0.3 indicated no correlation, −0.6 ≤ r < −0.3 indicated a weak negative (inverse) correlation, and r < −0.6 indicated a strong negative (inverse) correlation. Asterisks denote statistical significance (p < 0.05).CC BY · PubMed Central
Figure 2 FAP expression specifically labels CRC tissue. (A) Frequency of marker-absent (score 0), marker-low (score 1), and marker-high (score 2–3+) in CRC patient adjacent normal tissue samples for each CAF marker (αSMA, collagen, FAP, MMP2, PDPN, TAGLN, and THY1). (B) Correlations between marker expression scores in adjacent normal tissues across all CRC patients were evaluated by Pearson’s Correlation tests performed between all pairs of CAF markers. Strength of correlation was binned by correlation coefficient as in Figure 1C. Asterisks denote statistical significance (p < 0.05) (C) Ratio of the number of patients with marker-high cancer tissues to the number of patients with marker-high adjacent normal. For each marker, only patients with scorable cancer and normal tissues were considered (αSMA: n = 118, collagen: n = 155, FAP: n = 123, MMP2: n = 132, PDPN: n = 121, TAGLN: n = 109, THY1: n = 123) (D) Percentage of mCRC patients with negative staining in adjacent normal colon and liver tissue that had positive-staining colon cancer (pink) or metastases to liver (red). (E) Percentage of mCRC patients with negative staining in adjacent normal colon and liver normal tissue that had high staining in colon cancer (light blue) or liver metastases (dark blue).
Figure 2 FAP expression specifically labels CRC tissue. (A) Frequency of marker-absent (score 0), marker-low (score 1), and marker-high (score 2–3+) in CRC patient adjacent normal tissue samples for each CAF marker (αSMA, collagen, FAP, MMP2, PDPN, TAGLN, and THY1). (B) Correlations between marker expression scores in adjacent normal tissues across all CRC patients were evaluated by Pearson’s Correlation tests performed between all pairs of CAF markers. Strength of correlation was binned by correlation coefficient as in Figure 1C. Asterisks denote statistical significance (p < 0.05) (C) Ratio of the number of patients with marker-high cancer tissues to the number of patients with marker-high adjacent normal. For each marker, only patients with scorable cancer and normal tissues were considered (αSMA: n = 118, collagen: n = 155, FAP: n = 123, MMP2: n = 132, PDPN: n = 121, TAGLN: n = 109, THY1: n = 123) (D) Percentage of mCRC patients with negative staining in adjacent normal colon and liver tissue that had positive-staining colon cancer (pink) or metastases to liver (red). (E) Percentage of mCRC patients with negative staining in adjacent normal colon and liver normal tissue that had high staining in colon cancer (light blue) or liver metastases (dark blue).CC BY · PubMed Central
Figure 3 FAP expression across clinical subtypes of CRC. (A) Proportion of patients with EAO (light blue) or LAO (dark blue) disease and scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues. (B) Proportion of male (pink) or female (red) patients with scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues. (C) Proportion of patients with scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues across CRC disease stage. (D) Proportion of patients with FAP-absent, -low, and -high liver metastasis tissue given absent, low, or high FAP expression in their primary cancer tissue. (E) Primary cancer tissue FAP expression (absent, low, and high) across patients with left-sided, right-sided, and rectal primary tumors (F) FAP expression (absent, low, and high) across all CRC samples with high CD8+ T cell infiltration (CD8+ TILs > 5/HPF) compared to those with low CD8+ T cell infiltration (CD8+ TILs < 5/HPF).
Figure 3 FAP expression across clinical subtypes of CRC. (A) Proportion of patients with EAO (light blue) or LAO (dark blue) disease and scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues. (B) Proportion of male (pink) or female (red) patients with scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues. (C) Proportion of patients with scorable FAP-absent, FAP-low, and FAP-high primary cancer tissues across CRC disease stage. (D) Proportion of patients with FAP-absent, -low, and -high liver metastasis tissue given absent, low, or high FAP expression in their primary cancer tissue. (E) Primary cancer tissue FAP expression (absent, low, and high) across patients with left-sided, right-sided, and rectal primary tumors (F) FAP expression (absent, low, and high) across all CRC samples with high CD8+ T cell infiltration (CD8+ TILs > 5/HPF) compared to those with low CD8+ T cell infiltration (CD8+ TILs < 5/HPF).CC BY · PubMed Central
Figure 4 FAP expression across molecular CRC subtypes. (A) FAP expression in primary cancers tissues across APC, BRAF, KRAS, PIK3CA, and TP53 mutant and wild-type CRCs. (B) Percentage of dMMR and pMMR cancers with FAP-absent, -low, and -high primary cancers.
Figure 4 FAP expression across molecular CRC subtypes. (A) FAP expression in primary cancers tissues across APC, BRAF, KRAS, PIK3CA, and TP53 mutant and wild-type CRCs. (B) Percentage of dMMR and pMMR cancers with FAP-absent, -low, and -high primary cancers.CC BY · PubMed Central
Figure 5 CD8+ T cell infiltration varies with collagen abundance in the CRC TME. (A) Representative CD8+ T cell staining in FAP-low and FAP-high expressing primary CRC (top row). Representative CD8+ T cell staining in collagen-low and collagen-high expressing primary CRC (bottom row). (B) CD8+ TILs/HPF across CAF marker expression in all CRC tissues. ** p < 0.01 according to Wilcoxon rank sum test.
Figure 5 CD8+ T cell infiltration varies with collagen abundance in the CRC TME. (A) Representative CD8+ T cell staining in FAP-low and FAP-high expressing primary CRC (top row). Representative CD8+ T cell staining in collagen-low and collagen-high expressing primary CRC (bottom row). (B) CD8+ TILs/HPF across CAF marker expression in all CRC tissues. ** p < 0.01 according to Wilcoxon rank sum test.CC BY · PubMed Central
Figure 6 CAF markers are often co-expressed and associated with upregulation of inflammatory gene sets. (A) Groups of COADREAD cohort CRCs with intersecting and individual CAF marker expression. (B) GSEA comparing differential gene expression between intersecting or individual groups containing at least 5 CRCs vs. all other CRCs within the COADREAD dataset. Heatmap indicates –log10(FDR q-value) for each hallmark gene set by each group, where only statistically significant FDR q-values (q ≤ 0.05) are reported. Those groups with an FDR q-value > 0.05 for any given gene set were assigned a –log10(FDR q-value) of 0.
Figure 6 CAF markers are often co-expressed and associated with upregulation of inflammatory gene sets. (A) Groups of COADREAD cohort CRCs with intersecting and individual CAF marker expression. (B) GSEA comparing differential gene expression between intersecting or individual groups containing at least 5 CRCs vs. all other CRCs within the COADREAD dataset. Heatmap indicates –log10(FDR q-value) for each hallmark gene set by each group, where only statistically significant FDR q-values (q ≤ 0.05) are reported. Those groups with an FDR q-value > 0.05 for any given gene set were assigned a –log10(FDR q-value) of 0.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Li, H. (2013). Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM. arXiv.

Cited by

See all 18

Metadata

Authors
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
Deming, Dustin A.
Venue
Cancers
Publisher
MDPI AG
Published
2024-09-14
Volume
16
Issue
18
Pages
3158
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4402780081
Cited by
18
References
42
Citations by year
2026: 4 · 2025: 14
FWCI
3.08
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • JD Fluno Colorectal Cancer Precision Medicine Program (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • ACI/Schwenn Family Professorship (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • V Foundation (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • NRSA (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • NCI (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • NIH/NCI (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • 2018 Prostate Cancer Foundation Challenge Award (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
  • Prostate Cancer Foundation Young Investigator Award (T32 CA009135, R37 CA226526, R01 CA272855, R01 CA237272, R01 CA233562)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
colorectal cancer, cancer-associated fibroblasts, fibroblast activation protein, therapeutic target, tumor microenvironment, alpha-smooth muscle actin, podoplanin, MMP-2, transgelin, CD90, antibody conjugates, immune-related gene signature, therapeutic biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers. https://app.cochat.ai/papers/10.3390/cancers16183158
The paper
Shah, R., Johnson, K. A., Lippert, A. E. L., Kraus, S. G., Emmerich, P. B., Pasch, C. A., Zhang, W., Matkowskyj, K. A., LeBeau, A. M., & Deming, D. A. (2024). Cancer-Associated Fibroblast Proteins as Potential Targets against Colorectal Cancers. Cancers. https://doi.org/10.3390/cancers16183158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.